{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:54:23Z","timestamp":1707267263051},"reference-count":23,"publisher":"National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)","issue":"4","license":[{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp. oncol."],"abstract":"<jats:p>Background. The peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the most common subtype of peripheral T-cell lymphoma (PTCL). It constitutes approximately 25% of all PTCLs and accounts for more than 15% of all lymphomas. The results of the first Ukrainian prospective study of patients with PTCL-NOS are presented in the article. The aim of the study was to analyze the morbidity of PTCL patients and the treatment performed, to evaluate overall survival and progression-free survival, and to determine the factors that predict the treatment response. Patients and Methods. An analysis was performed on the data of 31 patients diagnosed with peripheral PTCL-NOS from February 2018 to the present. T-cell lymphoid neoplasms were diagnosed according to the 2016 WHO classification. The treatment regimens were in alignment with ESMO and NCCN guidelines. More than 90% of patients were prescribed anthracycline-based regimens (CHOP; CHOEP \u2014 cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone). An initial treatment was performed with CHOP-based regimens in 38.70% (n = 12) of patients, with the addition of etoposide in 58.06% of patients (n = 18). Results. The response was assessed according to the response criteria for malignant lymphoma (Cheson, 2008, 2014). The overall response to therapy was 58.06% (n = 18), with complete responses in 29.03% of patients and partial responses in 29.03% of patients. The stabilization of the disease occurred in 3.44%, while the disease progression in 41.37% of patients. The 12-month and 24-month survival rates were 75.44% and 50.81%, respectively. The 12-month and 24-month progression-free survivals were 47.68% and 33.1%, respectively. Ki-67 overexpression (&gt; 65%) was a negative prognostic factor. Conclusions. The results of the treatment of PTCL obtained in a Ukrainian population study are similar to those in other European studies, all of which remain unsatisfactory. Further research is required to develop a new strategy for examination and therapy to improve treatment outcomes. The emphasis should be placed on the pragmatic clinical trials comparing the efficacy of first-line treatment in PTCL patients with both favorable and unfavorable clinical factors.<\/jats:p>","DOI":"10.15407\/exp-oncology.2023.04.474","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T09:40:00Z","timestamp":1707212400000},"page":"474-482","source":"Crossref","is-referenced-by-count":0,"title":["NOT OTHERWISE SPECIFIED T-CELL LYMPHOMA: OUTCOMES OF A SINGLE CENTER STUDY"],"prefix":"10.15407","volume":"45","author":[{"given":"I.","family":"Kriachok","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Tytorenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Shudrak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Aleksik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya.","family":"Stepanishyna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Kadnikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya.","family":"Pastushenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Shokun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Rudiyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bushuieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"32237","published-online":{"date-parts":[[2024,2,3]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Vose J, Armitage J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell andnaturalkiller\/T-celllymphomastudy: pathologyfindingsandclinicaloutcomes. JClin Oncol. 2008;26(25):4124- 4130. https:\/\/doi.org\/10.1200\/JCO.2008.16.4558","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Zinzani PL, Broccoli A. T-cell lymphoproliferative disorders. In: Hoffbrand V, Higgs DR, Keeling DM, et al, eds. Postgraduate Hematology, 7th ed. Hoboken, NJ: Wiley Blackwell, 2016:524-536.","DOI":"10.1002\/9781118853771.ch28"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest. 2007;117(3):823-834. https:\/\/doi.org\/10.1172\/JCI26833","DOI":"10.1172\/JCI26833"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Iqbal J, Weisenburger DD, Greiner TC, et al; International Peripheral T-Cell Lymphoma Project. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115(5):1026-1036. https:\/\/doi.org\/10.1182\/blood-2009-06-227579","DOI":"10.1182\/blood-2009-06-227579"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Piccaluga PP, Fuligni F, De Leo A, et al. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol. 2013;31(24):3019-3025. DOI:10.1200\/JCO.2012.42.5611","DOI":"10.1200\/JCO.2012.42.5611"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Gallamini A, Stelitano C, Calvi R, et al; Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474-2479. https:\/\/doi.org\/10.1182\/blood-2003-09-3080","DOI":"10.1182\/blood-2003-09-3080"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24(16):2472-2479. https:\/\/doi.org\/10.1200\/JCO.2005.03.6327","DOI":"10.1200\/JCO.2005.03.6327"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Vose JM. International peripheral T-cell lymphoma (PTCL) clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines [abstract]. Blood. 2005;106(11):Abstract811. https:\/\/doi.org\/10.1182\/blood.V106.11.811.811","DOI":"10.1182\/blood.V106.11.811.811"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol. 2004;15(10):1467-1475. https:\/\/doi.org\/10.1093\/annonc\/mdh392.","DOI":"10.1093\/annonc\/mdh392"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Abramson JS, Feldman T, Kroll-Desrosiers AR, et al. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014;25(11):2211-2217. https:\/\/doi.org\/10.1093\/annonc\/mdu443.","DOI":"10.1093\/annonc\/mdu443"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Pinter-Brown L, Foss FM, Carson KR, et al. Patient characteristics and initial treatment patterns in the United States for the most common subtypes of peripheral T-cell lymphoma (PTCL) [abstract]. Blood. 2014;124(21):Abstract 4434.","DOI":"10.1182\/blood.V124.21.4434.4434"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Abouyabis AN, Shenoy PJ, Sinha R, et al. A systematic review and meta-analysis of front-line anthracycline- based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol. 2011; 2011:623924. https:\/\/doi.org\/10.5402\/2011\/623924.","DOI":"10.5402\/2011\/623924"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Briski R, Feldman AL, Bailey NG, et al. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer J. 2014;4:e214. https:\/\/doi.org\/10.1038\/bcj.2014.34","DOI":"10.1038\/bcj.2014.34"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High- Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418-3425. https:\/\/doi.org\/10.1182\/blood-2010-02-270785","DOI":"10.1182\/blood-2010-02-270785"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Corradini P, Tarella C, Zallio F, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia. 2006;20(9):1533-1538. https:\/\/doi.org\/10.1038\/sj.leu.2404306","DOI":"10.1038\/sj.leu.2404306"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"d'Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30(25):3093-3099. https:\/\/doi.org\/10.1200\/JCO.2011.40.2719","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;98(8):e81-e82. https:\/\/doi.org\/10.3324\/haematol.2013.084913","DOI":"10.3324\/haematol.2013.084913"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Bossard C, Dobay MP, Parrens M, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124(19):2983-2986. https:\/\/doi.org\/10.1182\/blood-2014-07-584953","DOI":"10.1182\/blood-2014-07-584953"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095-3100. doi.org\/10.1182\/blood-2013-12-542142","DOI":"10.1182\/blood-2013-12-542142"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Lamarque M, Bossard C, Contejean A, et al. Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients. Haematologica. 2016;101(3):e103-e106. https:\/\/doi.org\/10.3324\/haematol.2015.135400","DOI":"10.3324\/haematol.2015.135400"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Swerdlow S, Campo E, Pileri S, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569. https:\/\/doi.org\/10.1182\/blood-2016-01-643569","DOI":"10.1182\/blood-2016-01-643569"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Cheson B. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma. Radiol Clin North Am. 2008;46(2):213-223, vii. https:\/\/doi.org\/10.1016\/j.rcl.2008.03.003. DOI:10.1016\/j.rcl.2008.03.003","DOI":"10.1016\/j.rcl.2008.03.003"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Bellei M, Federico M. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: A report from the prospective International T-Cell Project. Haematologica. 2019;104:e178. https:\/\/doi.org\/10.3324\/haematol.2017.186577","DOI":"10.3324\/haematol.2017.186577"}],"container-title":["Experimental Oncology"],"original-title":[],"link":[{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/download\/2023-4-474\/2023-4-474","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/download\/2023-4-474\/2023-4-474","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T10:05:19Z","timestamp":1707213919000},"score":1,"resource":{"primary":{"URL":"https:\/\/exp-oncology.com.ua\/index.php\/Exp\/article\/view\/2023-4-474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,3]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2,3]]}},"URL":"https:\/\/doi.org\/10.15407\/exp-oncology.2023.04.474","relation":{},"ISSN":["2312-8852","1812-9269"],"issn-type":[{"value":"2312-8852","type":"electronic"},{"value":"1812-9269","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,3]]}}}